Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN HYDROCHLOROTHIAZIDE.
BENICAR HCT vs TELMISARTAN; HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Telmisartan is an angiotensin II receptor antagonist that selectively blocks the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Initial dose: 40 mg telmisartan/12.5 mg hydrochlorothiazide orally once daily. Titrate up to 80 mg telmisartan/25 mg hydrochlorothiazide once daily as tolerated.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Telmisartan: ~24 hours (range 18–24 h), enabling once-daily dosing. Hydrochlorothiazide: 6–15 hours (average ~9 h); prolonged in renal impairment.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Telmisartan: predominantly biliary/fecal (≥97%), renal <1%. Hydrochlorothiazide: predominantly renal (≥95%) as unchanged drug.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB